Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

BPC-157

Body Protection Compound-157, PL-14736, Pentadecapeptide BPC 157

Quick Stats
Studies 196
Trials 1
Score 3
2016 pubmed

Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.

Sikiric. Predrag P; Seiwerth. Sven S; Rucman. Rudolf R; Kolenc. Danijela D; Vuletic. Lovorka Batelja LB; Drmic. Domagoj D; Grgic. Tihomir T; Strbe. Sanja S; Zukanovic. Goran G; Crvenkovic. Dalibor D; Madzarac. Goran G; Rukavina. Iva I; Sucic. Mario M; Baric. Marko M; Starcevic. Neven N; Krstonijevic. Zoran Z; Bencic. Martina Lovric ML; Filipcic. Igor I; Rokotov. Dinko Stancic DS; Vlainic. Josipa J

Key Findings

  • BPC‑157 shows strong anti‑ulcer and gut‑protective effects and is safe in inflammatory bowel disease trials.
  • The peptide appears to protect and regenerate nervous tissue, helping after traumatic brain injury, spinal cord compression, and peripheral nerve cuts in animal models.
  • It modulates serotonergic and dopaminergic systems, improving behavioral disturbances linked to neurotransmitter imbalances.

Practical Outcomes

  • For biohackers, BPC‑157 looks like a potentially useful gut‑healing and neuro‑protective supplement, but current evidence is limited to animal work and early human safety data. There are no established dosing protocols yet, so anyone considering it should treat it as experimental and watch for emerging clinical trial results.

Summary

BPC‑157 is a stable 15‑amino‑acid peptide that naturally lives in the stomach. In animal studies and early human trials it looks safe and helps heal ulcers, gut damage, liver, pancreas, and even some brain injuries. It also seems to tweak serotonin and dopamine pathways, which could improve mood, movement, and nerve repair. While the data are promising, the research is still mostly pre‑clinical and doesn’t give clear dosing rules for everyday use.

Abstract

Brain-gut interaction involves, among others, peptidergic growth factors which are native in GI tract and have strong antiulcer potency and thus could from periphery beneficially affect CNS-disorders. We focused on the stable gastric pentadecapeptide BPC 157, an antiulcer peptidergic agent, safe in inflammatory bowel disease trials and now in multiple sclerosis trial, native and stable in human gastric juice. Review of our research on BPC 157 in terms of brain-gut axis. BPC 157 may serve as a novel mediator of Robert's cytoprotection, involved in maintaining of GI mucosa integrity, with no toxic effect. BPC 157 was successful in the therapy of GI tract, periodontitis, liver and pancreas lesions, and in the healing of various tissues and wounds. Stimulated Egr-1 gene, NAB2, FAK-paxillin and JAK-2 pathways are hitherto implicated. Initially corresponding beneficial central influence was seen when BPC 157 was given peripherally and a serotonin release in particular brain areas, mostly nigrostriatal, was changed. BPC 157 modulates serotonergic and dopaminergic systems, beneficially affects various behavioral disturbances that otherwise appeared due to specifically (over)stimulated/damaged neurotransmitters systems. Besides, BPC 157 has neuroprotective effects: protects somatosensory neurons; peripheral nerve regeneration appearent after transection; after traumatic brain injury counteracts the otherwise progressing course, in rat spinal cord compression with tail paralysis, axonal and neuronal necrosis, demyelination, cyst formation and rescues tail function in both short-terms and long-terms; after NSAIDs or insulin overdose or cuprizone encephalopathies were attenuated along with GI, liver and vascular injuries. BPC 157, a gastric peptide, may serve as remedy in various CNS-disorders.

Study Information

Provider

pubmed

Year

2016

DOI

10.2174/1570159x13666160502153022